Clinical trials: Malignancies Multiple
Colorectal Cancer, Non-small Cell Lung Cancer
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
This is a Phase 1 open-label, dose-escalation trial using "3+3" design, evaluating MM-151 co-administration with MM-121, MM-141, and trametinib at varying dose levels.
- Conditions
- Colorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02538627
- Testing
- MM-151, MM-121, MM-141
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Merrimack Pharmaceuticals
Diffuse Large B Cell Lymphoma (DLBCL)
Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy
Diffuse Large B-cell Lymphoma (DLBCL) is a common hematologic malignancy. Even after standard first-line treatment, approximately 40% of patients will experience relapse.
- Trial name
- NCT07310186
- Testing
- observational study
- Volunteers
- 200 people
- Sponsor
- Peking Union Medical College Hospital
Lymphoma, Multiple Myeloma
Lonquek for Autologous Stem Cell Mobilization
The aim of this study is to evaluate the efficacy and tolerability of Lonquek which is a pegylated (long-acting) version of Filgrastim recombinant human G-CSF (G-CSF) in mobilizing sufficient number of stem cells for autologous…
- Trial name
- NCT02488382
- Testing
- Lonquek
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Sheba Medical Center
Multiple Myeloma
Safety and Efficacy Assessments of Osalmid in Multiple Myeloma
This study aims to evaluate the safety and efficacy of a traditional cholagogue drug osalmid, 2-hydroxy-N-(4-hydroxyphenyl)-benzamide, in the treatment of multiple myeloma (MM).
- Trial name
- NCT03670173
- Testing
- Osalmid
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai 10th People's Hospital
Multiple Myeloma
A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure
The purpose of this observational study is to assess HRQoL in relapsed and/or refractory multiple myeloma (RRMM) participants who have previously received a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38…
- Trial name
- NCT05217082
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Bristol-Myers Squibb
Tuberous Sclerosis
Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)
To assess preliminary safety and efficacy of ganaxolone as adjunctive therapy for the treatment of primary seizure types in patients with genetically- or clinically-confirmed TSC-related epilepsy through the end of the 12 week…
- Trial name
- TSC (NCT04285346)
- Testing
- Ganaxolone
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Marinus Pharmaceuticals
Multiple Myeloma
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
The purpose of this open-label, non-randomized trial is to assess the safety and effectiveness of PXD101, both alone and in combination with dexamethasone, in patients with advanced multiple myeloma.
- Trial name
- NCT00131261
- Testing
- PXD101, Dexamethasone
- Where
- 10 sites in United States, Denmark and 2 more
- Volunteers
- 25 people
- Sponsor
- Valerio Therapeutics
Multiple Myeloma
Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
This is a multi-center, open-label, single arm, non-comparative phase II trial, designed to evaluate the efficacy of plitidepsin in combination with bortezomib and dexamethasone in patients with Multiple Myeloma (MM) double…
- Trial name
- NCT03117361
- Testing
- plitidepsin, Bortezomib, Dexamethasone
- Where
- 13 sites in France, Italy and 1 more
- Volunteers
- 10 people
- Sponsor
- PharmaMar
Histopathological Diagnosis of Nasopharyngeal Carcinoma, Patients with Nasopharyngeal Carcinoma Without Distant Metastases After AJCC/UACC 8th Edition
Prognostic Value of CD4/CD8 Ratio in Patients with Nasopharyngeal Carcinoma
In our previous retrospective study, we identified circulating immune cell counts and the CD4/CD8 ratio as significant prognostic markers in nasopharyngeal carcinoma.
- Trial name
- NCT06762470
- Where
- China
- Volunteers
- 325 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Breast Neoplasms, Neoplasm Metastasis
A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer
The main purpose of this research study is to see if the study drug, named CP-724,714, can help in the treatment of certain breast cancers that have spread to other locations in the body.
- Trial name
- NCT00102895
- Testing
- CP-724,714
- Volunteers
- 25 people
- Sponsor
- Pfizer
Multiple Myeloma
Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells
To evaluate the overall response rate, safety, and the 12-cycle clearance rate of circulating plasma cells (CPCs) in patients with newly diagnosed transplant-ineligible multiple myeloma stratified as high-risk based on…
- Trial name
- NCT07732712
- Testing
- Isatuximab, VRD
- Volunteers
- 15 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
Carcinoma, Non-small-Cell Lung
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in…
- Trial name
- PALOMA-2 (NCT05498428)
- Testing
- Amivantamab, Lazertinib, Carboplatin
- Where
- 110 sites in United States, Brazil and 10 more
- Volunteers
- 520 people
- Sponsor
- Janssen Research & Development, LLC
Non Small Cell Lung Cancer
Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy
This is a prospective multicenter clinical study. This study aims to construct an auxiliary decision-making system for lung cancer immunotherapy combined with radiotherapy by fusing three modes of imagomics, clinicopathological…
- Trial name
- NCT05584267
- Testing
- radiotherapy, Chemotherapy + immunotherapy
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Hunan Province Tumor Hospital
Triple Negative Breast Cancer
A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer
The current study is designed to evaluate the efficacy and safety of AL101 monotherapy in subjects with Notch-activated recurrent or metastatic TNBC; Notch activation will be determined by a Next Generation Sequencing (NGS) test.
- Trial name
- TENACITY (NCT04461600)
- Testing
- AL101
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 18 people
- Sponsor
- Ayala Pharmaceuticals, Inc,
Multiple Myeloma
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to…
- Trial name
- NCT06083207
- Testing
- IBI3003
- Where
- 13 sites in Australia, China
- Volunteers
- 116 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Plaque, Atherosclerotic, Programmed Cell Death Protein 1 Inhibitor
Multi-center Observational Study on the Progression of Atherosclerotic Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up
Multi-center Observational Study on the Progression of Atherosclerotic Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up
- Trial name
- NCT04922541
- Testing
- PD-1 inhibitor
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Locally Advanced Rectal Adenocarcinoma
INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer
Determine the complete pathologic complete response (pCR) rate in patients with locally advanced rectal adenocarcinoma.
- Trial name
- NCT04130854
- Testing
- APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days, mFOLFOX and Radiation Therapy 5Gy x 5 days
- Where
- 4 sites in United States
- Volunteers
- 58 people
- Sponsor
- University of Texas Southwestern Medical Center
Breast Cancer
Aromatase Inhibitor Clinical Trial
You are invited to participate in a research study looking at metabolism (breakdown) and effects of aromatase inhibitors. The purpose of this research is to try to identify which women who take an aromatase inhibitor are more…
- Trial name
- NCT00228956
- Testing
- pharmacodynamic analysis
- Where
- 3 sites in United States
- Volunteers
- 500 people
- Sponsor
- National Institute of General Medical Sciences (NIGMS)
Colorectal Cancer
Aspirin for Prevention of Postsurgical Recurrence and Metastasis in Asian Colorectal Cancer Patients: a Multi-center Randomized Trial
Background: Evidence of high quality has suggested that acetylsalicylic acid (ASA)/aspirin effectively reduces colorectal adenoma incidence and recurrence rate, and several randomized controlled trials (RCTs) strongly indicate…
- Trial name
- APREMEC (NCT02607072)
- Testing
- Acetylsalicylic acid (ASA)/aspirin 200 mg daily, Acetylsalicylic acid (ASA)/aspirin 100 mg daily
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- The Fourth Affiliated Hospital of Anhui Medical University
Multiple Myeloma
Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma
The present trial is designed as a phase II study that aims at estimating the efficacy of the combination of bendamustine, bortezomib and dexamethasone in relapsed/refractory multiple myeloma (MM). The response rate, i.e.
- Trial name
- BVD (NCT01045681)
- Testing
- Bendamustine, Velcade and Dexamethasone
- Where
- 37 sites in France
- Volunteers
- 75 people
- Sponsor
- Intergroupe Francophone du Myelome
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.